HAOHAI BIOTEC (06826.HK) spent 8.648 million yuan to repurchase 0.16 million A shares on April 16.

On April 16, HAOHAI BIOTEC (06826.HK) announced that it spent 8.648 million yuan on April 16, 2025, to repurchase 0.16 million A shares, with a repurchase price per share ranging from 53.66 to 54.5 yuan.

Gelonghui FinanceApr 16 05:36 ET

HAOHAI BIOTEC (06826.HK) held a Board of Directors meeting on April 25 to review and approve the first quarter results.

Gelonghui announced on April 11 that HAOHAI BIOTEC (06826.HK) will hold a Board of Directors meeting on April 25, 2025 (Friday) to review and approve the quarterly results and its release for the three months ending March 31, 2025.

Gelonghui FinanceApr 11 05:07 ET

HAOHAI BIOTEC: DATE OF BOARD MEETING

HKEXApr 11 05:06 ET · Announcements

HAOHAI BIOTEC (06826.HK) spent 15.2797 million yuan to repurchase 0.279 million A-shares on April 8.

On April 8, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced the repurchase of 279,000 A-shares for a total cost of 15.2797 million RMB on April 8, 2025, with the repurchase price ranging from 54.11 to 55 yuan per share.

Gelonghui FinanceApr 8 05:18 ET

HAOHAI BIOTEC (06826.HK) spent 11.5162 million yuan to repurchase 0.2203 million A-shares on April 7.

On April 7, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced the repurchase of 0.2203 million A-shares at a cost of 11.5162 million yuan on April 7, 2025, with a repurchase price ranging from 49.25 to 54.97 yuan per share.

Gelonghui FinanceApr 7 05:41 ET

Shanghai Haohai Biological Technology (688366.SH): A total of 0.8267 million shares of the company's A-shares have been repurchased.

Gelonghui, April 1 - Shanghai Haohai Biological Technology (688366.SH) announced that as of March 31, 2025, the company has cumulatively repurchased 0.8267 million A-shares through centralized bidding trading, accounting for 0.35% of the company's total share capital. The highest Fill Price was 63.58 yuan/share, the lowest Fill Price was 56.78 yuan/share, and the total amount reached 50.4938 million yuan (excluding stamp duty, trading commission, and other transaction fees).

Gelonghui FinanceApr 1 05:18 ET

HAOHAI BIOTEC (06826): Gan Renbao is no longer serving as the company's core technical personnel.

HAOHAI BIOTEC (06826) announced that Mr. Gan Renbao, a core technical personnel, will no longer serve due to advanced age...

Zhitong FinanceMar 28 06:26 ET

Shanghai Haohai Biological Technology (HKG:6826) Sheds 6.4% This Week, as Yearly Returns Fall More in Line With Earnings Growth

Simply Wall StMar 25 21:49 ET

Zhitong Hong Kong stock repurchase Statistics | March 26

Hong Kong stock repurchase Statistics | March 26th

Zhitong FinanceMar 25 21:10 ET

HAOHAI BIOTEC (06826.HK) spent 0.5422 million HKD to repurchase 0.02 million shares on March 25.

On March 25, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced it spent 0.5422 million Hong Kong dollars to repurchase 0.02 million shares on March 25, 2025, with a repurchase price of 27.1-27.15 Hong Kong dollars per share.

Gelonghui FinanceMar 25 05:29 ET

Haohai Biological Technology's Profit Jumps 1% in 2024

MT NewswiresMar 24 07:44 ET

Shanghai Haohai Biological Technology 2024 Annual Report: The proportion of medical aesthetics business has further increased, and the impact of policies such as centralized procurement has not yet faded.

① The medical beauty Sector achieved revenue of 1.195 billion yuan, a year-on-year increase of 13.08%, with the business proportion rising from 39.96% to 44.38%, becoming the core driving force behind the company's current performance growth. ② Compared to the "counter-trend growth" of the medical beauty Sector, multiple sectors of Shanghai Haohai Biological Technology experienced varying degrees of revenue decline, and have not yet overcome the painful adjustment period of policies.

cls.cnMar 22 03:10 ET

Haohai Biotech: Summary of the 2024 Annual Report of Shanghai Haohai Biotechnology Co., Ltd.

SZSIMar 21 12:00 ET · Announcements

Haohai Biotech: Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual Report

SZSIMar 21 12:00 ET · Announcements

Summary of the 2024 Annual Report of Shanghai Haohai Biotechnology Co., Ltd.

SZSIMar 21 12:00 ET · Announcements

Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual Report

SZSIMar 21 12:00 ET · Announcements

HAOHAI BIOTEC (06826) intends to re-appoint Ernst & Young Hua Ming Accounting Firm.

HAOHAI BIOTEC (06826) announced that the company intends to reappoint Ernst & Young Hua Ming Accounting Firm (special general partnership)...

Zhitong FinanceMar 21 09:35 ET

Express News | Shanghai Haohai Biological Technology FY Basic EPS RMB 1.8

ReutersMar 21 09:08 ET

Express News | Shanghai Haohai Biological Technology FY Dividend RMB 0.6

ReutersMar 21 09:08 ET

Express News | Shanghai Haohai Biological Technology FY Gross Margin 69.74%

ReutersMar 21 09:08 ET